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Abstract: 
Elucidating details of the relationship between molecular structure and a particular biological end point is essential for successful 
rationally-based drug discovery. Molecular docking is a widely accepted tool for lead identification however navigating the 
intricacies of the software can be daunting. Our objective was therefore to provide a step-by-step guide for those interested in 
incorporating contemporary basic molecular docking and homology modelling into their design strategy. Three molecular 
docking programs, AutoDock4, SwissDock and Surflex-Dock, were compared in the context of a case study where a set of 
steroidal and non-steroidal ligands were docked into the human androgen receptor (hAR) using both rigid and flexible target 
atoms. Metrics for comparison included how well each program predicted X-ray structure orientation via root mean square 
deviation (rmsd), predicting known actives via ligand ranking and comparison to biological data where available. Benchmarking 
metrics were discussed in terms of identifying accurate and reliable results. For cases where no three dimensional structure exists 
we provided a practical example for creating a homology model using Swiss-Model. Results showed an rmsd between X-ray 
ligands from wild-type and mutant receptors and docked poses were 4.15Å and 0.83Å (SwissDock), 2.69Å and 8.80Å 
(AutoDock4) and 0.39Å and 0.71Å (Surflex-Dock) respectively. Surflex-Dock performed consistently well in pose prediction 
(less than 2Å) while AutoDock4 predicted known active non-steroidal antiandrogens most accurately. Introducing flexibility into 
target atoms produced the largest degree of change in ligand ranking in Surflex-Dock. We produced a viable homology model of 
the P2X1 purireceptor for subsequent docking analysis.  
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1. Introduction 
 A key goal in many medicinal chemistry projects is 
to synthesize a database of compounds which promote or 
inhibit a particular biological action, typically mediated by a 
receptor or enzyme. Furthermore, the added commercial 
necessity to facilitate this process within a minimum of 
synthetic steps, cost or timeframe expounds the difficulties 
synthetic chemists face.  Development of a lead compound 
through to clinical trials can take up to fourteen years and at 
an expense of around US800 million.[1] Computational 
approaches hold a valid place in the overall strategy yet the 
ability to accurately predict binding affinity is still 
challenging.[2, 3] The availability of high resolution 
structural data facilitates receptor-based design providing 
valuable insight into the molecular interactions between 
potential drugs and their targets. Engaging in receptor-based 
design and its incorporation into drug design, though 
desirable, can be a daunting prospect for many researchers. 
 
Advances in computational power have facilitated 
modelling of more complex biomolecular systems such as the 
temporal passage of ions through membranes.[4-6] More 
realistic representations of biological systems are always 
desired as is the ability to accurately predict the interactions 
between a biological target and a ligand.  Key barriers to this 
problem include accurately accounting for entropic 
contributions to the overall binding free energy (derived from 
desolvation or solvent effects) and conformational changes of 
protein and/or ligand.[7, 8] Apart from its role as a biological 
solvent, water functions in many biological processes such as 
desolvation, binding, stabilization and catalysis. Including 
explicit solvent molecules in a calculation however 
exponentially increases CPU time thus it is unsurprising that 
many algorithms simulate implicit solvent with the most 
common model being the Generalized Born (GB)/Surface 
Area model.[9] A comparison of free energy predictions by 
various GB models incorporating implicit solvent with 
dielectrics ranging from five (non-polar) to eighty (aqueous) 
with previous calculations using explicit solvent demonstrated 
that for high dielectric field environments where hydrogen 
bonding is important, the results were much less favourable 
than for those in a binding pocket or in a membrane 
interior.[10] This clearly demonstrates the importance of 
including explicit solvent in calculations for aqueous or polar 
systems.  
 
Techniques for molecular modelling can be broadly 
divided into those models that are based on quantum physics 
and those that are not. Of the former, ab initio methods are 
based solely on approximations to the Schrὂdinger equation, 
focus on electronic systems and involve no experimental data. 
Semi-empirical methods incorporate experimental parameters 
and extensive approximations to the Schrὂdinger equation 
while molecular mechanics focuses on atomic nuclei utilizing 
classical mechanics. Molecular mechanics (MM) treats 
molecules as a system of balls (atoms) and springs (covalent 
bonds). Parameters for the various atoms and bond types, 
derived from experiment or ab initio methods, contribute to 
the potential function for the system called a force field. MM 
methods are best suited therefore to intramolecular analyzes 
such as conformational analyzes and determination of 
dynamic properties of molecules. Quantum mechanics (QM) 
is preferred when intermolecular interactions are of interest 
since electrons govern these short-range interactions. At 
present, however, system sizes are limited to less than one or 
two hundred atoms which is miniscule for a biological system. 
Therefore while QM techniques are preferable, in many cases 
biomolecular systems, modelled in their entirety, are 
somewhat restricted to MM techniques. More recently, 
combined QM/MM techniques have been developed. In these 
models, QM is often used to model interactions between a 
ligand bound into a binding site and MM for the remainder of 
the biomolecule.[11] 
 
1.1 Molecular Docking 
Among the most common MM techniques, molecular 
docking (MD) provides a convenient way to leverage 
structure for ligand discovery. Compared to laboratory-based, 
serendipitous, high throughput screening (HTS), MD can 
access far more chemistry more quickly and with far less 
cost.[12]  Molecular docking is an MM approach to ‘fit’ a 
ligand into a three-dimensional binding site. Two operations 
are involved. Firstly a search of conformational space 
available to a ligand followed by a scoring function 
representing binding affinity. Despite the differences in these 
operations, MD programs often use the same algorithm for 
both tasks. Some may include a facility to perform consensus 
scoring when a number of algorithms have been included. 
Algorithms differ in the weight given to particular non-
covalent interactions and/or entropic parameters producing a 
diverse set of results for the same ligand database in the same 
target. Understanding the particular emphasis given to these 
parameters for a chosen algorithm helps the interpretation of 
this diversity. Consensus scoring has been shown to reduce 
the prevalence of false positives in a docking study.[13] 
 
MD uses a stochastic, or random, searching algorithm and 
thus, can be limited by the time allocated to the search. There 
is an obvious trade-off between accuracy and time since the 
longer the process is allowed to proceed, the more likely it will 
be to find the global minimum conformation. This assumes 
this lowest energy conformation is indeed the biologically 
relevant orientation however this is not always the case as in 
transition state models. Additionally a deep, narrow energy 
well may not be the more preferred as it ignores entropic 
considerations.  
 The docking process is remarkably fast if target atoms are 
kept rigid though the more patient user can expect higher 
quality results when the target incorporates flexibility in 
protein side chains. Depending on the computer system, target 
biomolecule and number of ligands used in these calculations, 
a single flexible docking can be performed in around one 
minute.[14, 15] Algorithms which are capable of flexible 
backbone and sidechain atoms will be orders of magnitude 
more complex and therefore more time and computationally 
expensive. 
 
Assessing an MD algorithm’s ability to successfully search 
conformational space in which to fit a ligand is usually done 
by comparing the conformations of X-ray and docked ligand 
poses. This assumes however there has been no change in 
conformation of the ligand from solution state to crystal 
structure. Determination of root mean square deviation (rmsd) 
provides a quantitative measure of comparison. MD scoring 
functions are considered to adequately reproduce the bound 
conformations as the global (or local) minima if less than the 
accepted level of 2Å.[16, 17] 
 
The docking algorithm can be further assessed by 
determining its capacity to find a known inhibitor amongst a 
large set of mostly random non-bonding compounds or 
decoys. Note that a program that finds the ‘correct’ pose for a 
single ligand may not also be good at comparing molecules.  
 
Docking algorithms must rank compounds in terms of 
binding affinity which may or may not bear any relation to 
activity. Binding free energy is an ensemble property 
(dependent on all possible states) and a statistical mechanics 
problem. Algorithms estimating this property from a single 
state (that is, the crystal structure) will therefore be 
unsatisfactory. A workaround is to conduct virtual screening 
in which known binding compounds are seeded into a small 
database of compounds. Algorithms able to score these known 
binding compounds amongst the higher scoring compounds is 
desirable. There is of course an underlying assumption that the 
scoring actually infers binding affinity but, as mentioned 
above, this is not necessarily the case. Strategies for validating 
predictions include benchmarking with other programs and 
comparison to biological assay data if available. With over 
sixty different molecular docking algorithms available each 
employing one of over thirty different algorithms selecting an 
appropriate program appears the first of many questions to be 
answered. Biological endpoints of interest are quoted in 
diverse units from IC50 to Ki further limiting direct 
comparison. 
 
Three key limitations of MD are the inability to accurately 
model solvent, entropy and target flexibility. Performance can 
be tracked by including known actives as well as other, mostly 
random non-bonding compounds (decoys). Large 
benchmarking sets which aid the ligand enrichment process 
are available for well-known targets.[18] Decoys should 
ideally possess a degree of structural similarity to the active 
compounds for fair comparison of at least be drug-like and can 
be sourced from a number of databases. The latter strategy of 
ligand enrichment among top-ranking hits is a key metric of 
molecular docking. While MD has a relatively low success 
rate in the translation of top-scoring molecules to hits with 
actual binding affinity however, it is an important tool since 
the generation of a few compounds with new chemistry 
remains of interest. 
 
This review provides a practical guide to MD and 
homology modelling for those wishing to integrate 
computational methodologies into their design process. Three 
molecular docking programs, AutoDock4[19], 
SwissDock[20, 21] and Surflex-Dock[22], are compared in a 
test case involving the human androgen receptor (hAR) target 
and androgen receptor inhibitor database. The hAR is an 
important therapeutic target and several 3D structures are 
available. We chose to compare the wild type hAR with a 
mutant containing a commonly observed mutation leading to 
castration resistant prostate cancer. In this case, the mutation 
creates a larger binding pocket into which ligands may 
interact. Most MD tutorials contain instructions on simply 
producing MD data which is often a relatively rapid process. 
However we provide a more complete workflow including 
interpretation of the data. We also compare the programs’ 
functionalities as demonstrated within this case study. 
Additionally, for those cases where an X-ray structure is 
unavailable, a homology modelling case study is provided 
using Swiss-Dock to build a model of the P2X1 purinergic 
receptor. Tips and limitations are provided as well within each 
technique. It is beyond the scope of this guide to provide a 
comprehensive review of computer-aided drug design in 
general and a detailed description/comparison of forcefields 
and other parameters has been purposely left out for simplicity 
although links to relevant resources are provided. The reader 
is directed to the following comprehensive reviews.[23, 24] 
 
1.2 Selecting a Suitable Program 
Selecting a suitable MD program depends on a number of 
considerations such as cost, ease of use, computational 
capacity, etc. Once selected it is important to conduct 
appropriate validations and benchmarking against other 
docking algorithms. At the end of this review, we have 
included a comparison of features of the selected MD 
programs as an example of key features to consider. 
 
Many docking programs are available and their 
performance recently reviewed.[25] We have selected three 
programs which represent various user preferences for 
freeware, online server access only and commercial software. 
SwissDock[20] represents a choice for those wanting to 
conduct MD on an online server. One of the gold standard MD 
programs commonly used is the freeware package, 
AutoDock4[19, 26] (AD4), developed by the Scripps Institute 
[27].  Finally we’ve selected the MD package Surflex-Dock 
included as part of the commercially available molecular 
modelling suite of applications, Sybyl-X [28].  
 
1.3 Resources for Structural Data 
The Protein Data Bank (PDB) (www.rcsb.org) is one of a 
few indispensable global repositories archiving the 
experimentally-derived atomistic models of biological 
entities, including proteins and nucleic acids.[29] Curation 
and management of the world wide PDB is jointly performed 
by the four partners: Research Collaboratory for Structural 
Bioinformatics (RCSB), PDB from Europe and Japan and the 
Biological Magnetic Resonance Bank (BMRB).  The database 
contains structures of biomolecules produced by X-ray 
crystallography, NMR, electron microscopy of a hybrid 
approach. The X-ray structures are an interpretation of the 
electron density of a static molecular system. Though X-ray 
crystallography produces the most highly resolved structures, 
biological systems are inherently dynamic and this remain a 
limitation of the technique. At the time of writing there are 
almost 113,000 biological structures in the database, around 
30,000 of which are protein structures of human sequences. In 
stark contrast there are around 560 unique membrane proteins 
currently in the database of Membrane Protein of Known 
Structure and around 2,600 transmembrane proteins in the 
Protein Databank of Transmembrane Proteins (PDBTM). One 
reason for this is that soluble biomolecules are experimentally 
more facile to crystallize. Unfortunately it is the latter that 
many medicinal chemists aim to target since, for example, 
nearly half of all drugs target membrane-bound G-protein 
coupled receptors. [30]  
 
Many of the entries contain small molecules that may be 
non-covalently incorporated ligands, cofactors or ions or 
modified or uncommon amino acids within the polymer. 
Within the PDB, these small molecules have been annotated 
and collated into a chemical database (CCD). Small, 
biologically-relevant peptide-like antibiotic and inhibitor 
molecules present in the PDB have recently been collated the 
Biologically Interesting molecule Reference Dictionary 
(BIRD) (similar to Chemical Components Dictionary) which 
can be searched or downloaded for analysis. BIRD entries 
may appear as a polymer or ligand (or both) providing 
sequence or chemical information respectively. Annotations 
have been extensively classified and searches within the PDB 
can produce a great deal of useful information.[31] 
 
Knowledge of the three dimensional (3D) structure of 
biological targets provides the platform from which receptor-
based modelling techniques can be performed. Due to the 
disparity in available structural target information other 
computational approaches are required.  Under these 
circumstances 3D homology models can be generated from 
amino acid sequences of the target of interest if, for example, 
the 3D structure of a similar target, perhaps of the same 
family, is known. Another approach, in the absence of a 3D 
structure, is the ligand-based approach producing a 
pharmacophore model prepared from a library of ligands with 
known binding affinities with a particular target.   
 
Preparation of target and ligands prior to analysis is a key 
aspect to the success of an MD analysis. Although high 
resolution structures are available, it is essential to keep in 
mind that X-ray crystallography data is subjective in the 
interpretation of electron density and other interpretations 
may exist. Furthermore, conformations in the solution state 
may differ markedly from those in the crystalline form 
required for crystallography. While errors in interpretation of 
entire protein structures are rare, careful inspection is 
required. For instance, many flexible regions in a protein are 
often undefined and their respective x,y,z coordinates are 
therefore omitted. Chirality of ligands can sometimes be 
interpreted incorrectly as has been recently highlighted for 
oligosaccharide [32]. Correct positioning of water, sidechains 
of glutamine, asparagine and histidine is often challenging for 
crystallographers.[20] Protonation state of any residues within 
the binding site should be assessed prior to MD. A report to 
check target structure can be obtained at the PDB. Careful 
attention to ligand topology is essential to assess the treatment 
of tautomers, protonation states or other physicochemical 
features. 
 
1.4 Selected MD programs  
1.4.1 SWISSDOCK server 
SwissDock, developed by the Molecular Modellers Group 
at the Swiss Institute for Bioinformatics, is a free service for 
academic users wanting to dock a set of ligands to a target 
biomolecule using a docking server. While there is a vast 
amount of information published regarding SwissDock as a 
docking tool, to the best of our knowledge there is no 
information available which adequately explains its use to the 
average chemist.   
 
SwissDock presents an intuitive graphical user interface 
(GUI) clearly setting out tabs for submitting docking runs 
providing access to some general algorithm information and 
examples. SwissDock’s algorithm is based on the dihedral 
space sampling (DSS) in EADock which, depending on the 
nature of the target and ligand, generally performs a fast, 
single step process, with little user-controlled input. Results 
can be used as a seed generator for further docking. Energy 
calculations are performed using the CHARMM (Chemistry 
at HARvard Macromolecular Mechanics) forcefield on the 
Vital IT cluster computer. Cluster groups of docked poses are 
scored and the results can be downloaded. MD runs are 
queued and delays can occur as a result. Results are stored for 
one week on the server. An option for private use is available. 
 
SwissDock performs single ligand docking.  For ligand 
databases, each must be docked individually. This can be 
burdensome for large ligand libraries.  Scripts are available 
elsewhere for automating multiple-ligand docking however 
this is beyond the scope of this review. SwissDock is also 
unable to dock single ligands into multiple targets. 
 
In the absence of a grid box definition, SwissDock server 
will perform a ‘Blind Docking’ whereby the algorithm 
searches for thermodynamically favourable sites into which to 
bind the ligand.  However, since many binding sites are 
located within a crevice or channel and therefore may be 
ignored by the program. Toggling between accuracy levels 
from ‘Very Fast’, to ‘Fast’ or to ‘Accurate’, marginally 
increases the likelihood of obtaining a binding mode that 
correctly predicts promising binding conformations such as 
that found from a crystal structure from 62%, to 63% and to 
64% respectively.   
 
1.4.2 AUTODOCK 4 (AD4) 
AD4 and AutoDockTools (ADT) are freely available 
automated docking software packages developed by the 
Department of Molecular Biology at the Scripps Research 
Institute, La Jolla, CA and the Department of Cognitive 
Science at the University of California, San Diego, La Jolla, 
CA. 
 
 AD4 (version 4.2) is a standalone cross-platform 
application operating on Linux, Mac OS, Windows and Sun 
Solaris operating systems.  Intel i86 (32-bit), x86_64 (64-bit), 
and PowerPC processors are supported.  ADT is the graphical 
front-end, python molecular viewer for using AD4 and is 
included as part of a package known as MGLTools, also 
provided by the Scripps Research Institute.[33] [34] A key 
benefit to using AD4-based programs is that they are Industry 
standards, robust and cost free. By using different front-end 
software, it is possible to complete the entire analysis within 
a GUI environment.  Virtual screening is also possible using 
a software package known as PyRx.[35] Section 2.2.2 focuses 
on guiding the reader through the use of AD4 via the ADT 
front-end to dock the ligand dataset into the hAR target. We 
also demonstrate how to do multiple ligand screening using 
the PyRx front-end GUI.[19] 
 
1.4.3 SURFLEX-DOCK 
Surflex-Dock[36], developed by Tripos, is a commercially 
available ligand-receptor docking and virtual screening 
program and is part of the SYBYL-X suite of molecular 
modelling package.[28] Although users of SYBYL have 
access to extensive help documentation and tutorials, we 
provide a basic workflow using Surflex-Dock to perform the 
same docking analysis as shown with the previous two 
packages.  The main benefits of Surflex-Dock include a robust 
algorithm, easy target/ligand preparation, comprehensive 
user-control over the docking process; consensus scoring, 
protomol guided docking, rigid and flexible docking including 
ring flexing, ability to dock large libraries of ligands and 
parallelization. 
 
Setting up an MD run with Surflex-Dock can be easy when 
default settings are maintained. We recommend initially 
leaving settings for the protomol size and docking parameters 
at default values until the user becomes more familiar with the 
various functionalities and how they affect the results. 
Experienced users can achieve a higher level of accuracy and 
specificity via the high level of user control. Surflex-Dock 
makes use of a protomol rather than a grid box functionality 
to define conformational space when bound ligands are 
available. During docking the ligands are fragmented and each 
fragment used to search available space. High scoring 
fragments are retained and the final ligand reconstructed from 
those high scoring fragments. In the absence of a bound ligand 
key target residues can be selected otherwise the software is 
able to predict potential binding sites in a third option. 
 
1.5 Homology Modelling  
Protein sequences are the fundamental determinants of 
biological structure and function.[37] The field of structural 
biology has provided a plethora of knowledge on protein 
structure enabling prediction for the translation of a protein’s 
primary sequence, through secondary structure (such as alpha 
helices, beta sheets, turns etc) to common motifs, domains, 
folds, tertiary and even quaternary arrangement of 
subunits.[38] Homology modelling is a technique which 
builds a 3D structure from a protein sequence of interest based 
on the 3D structure of a similar protein. In the absence of an 
available crystal structure for a protein of interest, a homology 
model can provide an alternative for subsequent receptor-
ligand analyses such as molecular docking or dynamics as 
long as a three dimensional structure exists for a similar 
protein. Recent results from the 10th Critical Assessment of 
Structure Prediction (CASP) showed a dramatic increase in 
accuracy of homology models.[39]   
 
An inherent problem in homology modelling is that two 
proteins may be almost identical structurally yet share very 
little sequence homology.[40] This has been somewhat 
overcome by fold-recognition technologies.[41] A sequence 
identity of 35% or higher is considered a rule of thumb for 
reliable homology modelling [42, 43] although such a cutoff 
may miss some structural or evolutionarily-related template 
sequences. Inaccuracies between template and models can 
also result from difficulties modelling loop regions caused by 
insertions or deletions in the sequence. Loop regions are often 
functionally important as sites for ligand attachment or as part 
of a regulatory mechanism. Loops can be treated either by 
comparison to a database of loop conformations of similar 
sequence or by energy minimization techniques.[44] Other 
functional domains however, such as active sites, are 
generally well conserved.[45] Despite a number of other 
limitations, including side chain conformations, resulting in 
sources of error in the model structures even low-accuracy 
structures can still be useful for investigating hypotheses 
about binding site location, substrate specificity and drug 
design.  
 
Swiss-Model is an automated comparative protein 
modelling server freely accessible to non-commercial users 
via the Expasy server.[46-48] The basic workspace provides 
users the opportunity to save their work and develop their 
models. Most often you will have a clear idea of the molecular 
target to which you are designing molecular modulators.  The 
National Centre for Biotechnology Information (NCBI), 
(http://www.ncbi.nlm.nih.gov/) is a good place to start your 
search for an amino acid sequence for your target protein.  
Sequences are input in FASTA format, ubiquitous in 
molecular biology.  
 
SwissProt initially searches the PDB for three dimensional 
structures that match your query sequence.  The user selects a 
template from the returned matches.  In general, the most 
suitable template will be that with the highest level of 
sequence identity. SwissProt operates in three modes, 
automated, alignment and DeepView Project mode. 
 
Accuracy of 3D template structure is reflected in the 
resolution (in Å) whereby the lower the better. This ranges 
from excellent (~1Å) to poor (>3.5Å).  Resolution represents 
the average uncertainty for all atoms. Uncertainty increases 
with disorder in the protein crystal during the crystallography 
process. Note that temperature (or B) factors represent the 
uncertainty for individual atoms. A high temperature factor 
represents a low empirical electron density for the atom. A 
range of acceptable values signifying reasonable position 
confidence would be 30Å2-60Å2.  
 
SwissProt conducts a sequence similarity search of the 
PDB using the BLOSUM62 similarity matrix function. 
Homology models are assessed by a QMEAN4 scoring 
function for the estimation of the global and local model 
quality.[49] QMEAN4 consisting of four structural 
descriptors. A torsion angle potential over three consecutive 
amino acids, two pairwise distance-dependent potentials and 
a solvation potential describes the burial status of the residues. 
A Global Model Quality Estimation (GMQE), a number 
between 0 and 1, is used to reflect the reliability of the model 
with one reflecting the most reliable. 
 
One of the main limitations of homology modelling 
includes a lack of suitable/reliable templates. Most structures 
in the PDB are of crystallographic origin and the majority of 
those represent fragments of the full-length proteins - often 
not more than 30% of the query sequence of interest. NMR 
solution structures are generally smaller monomeric proteins 
with an average of 90 amino acids. Highly disordered X-ray 
data can result in missing residues in template structures 
propagating further errors in the final model. Errors or 
uncertainties in the sequence alignment result in erroneous 
homology models. The quality of the alignment is crucial for 
a reliable model.  In many cases models cannot correctly 
predict sidechain rotamer positions since correct geometries 
are not part of the homology model generation algorithms. 
(Rotamers are different conformations of a sidechain in three-
dimensional space) Errors are likely with respect to steric 
clashes, electrostatic repulsions etc. These effects may or may 
not be minimized by subsequent energy minimizations. 
1.6 Scope 
The purpose of this review was to provide a practical guide 
on incorporating MD into a design strategy by way of 
comparing three commonly used MD programs.  
Additionally, in cases where no crystal structure exists, a 
practical guide to homology modelling has also been 
included. It was assumed the reader possesses a basic 
familiarity with computers operating on either a Windows or 
Linux platform and write access for program installation. 
 
The case study involved docking a set of androgen 
modulators into the wild type and mutant human androgen 
receptor sites. The database comprised known actives, decoys 
and a novel set of androgen receptor inhibitors.[50] Large 
datasets of active compounds as well as decoys specifically 
for the androgen receptor, designed for 3D virtual screening, 
were sourced from the database of useful decoys (DUD).[51] 
Figure 1: Basic workflow for molecular docking. 
 
A basic molecular docking workflow is presented in Figure 
1. 
2. Method 
2.1 Ligand Database and Target Preparation 
A small subset of steroidal and non-steroidal androgen 
receptor inhibitors along with native steroids and decoy 
(n=11) were prepared in SYBYLx-2.1 with hydrogens and 
Gasteiger-Hűckel charges added prior to energy 
minimization.  Correct protonation was used where 
applicable. A structural similarity map was prepared which 
aids in grouping by structural features (Supplementary Figure 
S1). Biological, physical and chemical properties were 
determined for each ligand for subsequent correlation analysis 
and set out in Supplementary Table S1. 
 
The wild type and mutant hAR structures, 2PNU and 2OZ7 
respectively, were prepared with hydrogens and Gasteiger-
Hűckel charges and ligands removed prior to energy 
minimization.  
2.2 Molecular docking of androgen receptor inhibitors  
2.2.1 MD using SwissDock 
For non-specialists, setup of the target/small molecule 
docking process using SwissDock is intuitive and fast. While 
a command line option is available for experienced molecular 
modelers we recommend reading the associated 
documentation and practicing with provided tutorials to 
become more familiar with parameter functionality as default 
values may not always be appropriate. From the online server, 
results can often be returned within around thirty minutes 
depending on server queues, grid box size, exhaustive search 
parameters and flexibility options. Automated docking can be 
facilitated via the programmatic SOAP (Simple Object 
Access Protocol) interface supplying template scripts which 
can be downloaded in Perl, Python and PHP. 
 
Table 1: Practical Guide to MD using SwissDock 
 
Step Task Comments/recommendations 
1 Target preparation.  Remove ligand and any other non-protein 
molecules. This may be performed in JMol [52] 
or other molecular visualization program. 
1 Upload crystal structure 
via ‘Target Selection 
’tab 
PDB or CHARMM file formats can be 
accepted. CHARMM input files are also 
accepted including coordinate file (PDB), extra 
topology (RTF) and parameter files (PAR). 
2 Upload ligand files via 
the ‘Submit Docking’ 
tab. 
(see note below on 
multiple ligand docking)  
Prepare single or multiple ligand files in .mol2 
format. Alternatively ZINC database identifiers 
can be used to access a large ligand library. 
Add hydrogens, check chirality, protonation 
state and topology. Prior energy minimization 
of the ligand is not required.  
3 Add ‘Extra 
Parameters’ 
Select one of three levels of accuracy, Very 
Fast, Fast or Accurate, reflecting parameters 
such as binding mode (BM), sample size, 
number of minimization steps and number of 
BMs. Note for ligands with less than 15 
rotatable bonds or those likely to fit exactly into 
a particular pocket, the first two modes may be 
suitable. 
4 Specify ‘Region of 
Interest’ to limit 
docking to a specific site 
(Local Docking). Select 
x,y,z coordinates (in Å) 
for the centre point and 
size of the Grid Box. 
Units must be in Angstroms, Å, and correct to 
two decimal places. Coordinates for a grid-box 
can be obtained from AutoDock Tools, 
however, x,y,z sizes for this grid-box generated 
by AutoDock Tools will be given in Grid-Box 
Units, which are 0.375Å each, and so a box with 
dimensions of 40×40×32 Grid-Box Units 
generated in AutoDock Tools must be 
converted to the equivalent dimensions of 
15×15×12Å for use in SwissDock. 
5 Specify residues for 
flexible docking via the 
‘Flexibility’ tab. 
Select side-chains within 0, 3 or 5Å of a ligand.  
6 ‘Submit docking’ Results sent by email with a link to SwissDock 
where the results may be viewed.  
7 Assessment of docked 
poses.  
A more comprehensive results assessment can 
be carried out using UCSF Chimera [53]. A 
direct link is provided with the results where 
poses can be assessed and compared in relation 
to the protein target. Scores are provided in 
units of estimated free energy or full fitness. 
2.2.2 MD Using AUTODOCK 
Download and install both AD4 and ADT from the Scripps 
Research Institute’s website. Calculations are performed in 
several steps. First is the preparation of coordinate files using 
ADT followed by pre-calculation of atomic affinities using 
AutoGrid prior to the docking of ligands using AD4. Analysis 
of results is performed using ADT. 
 
The python molecular viewer’s main screen provides 
access to various computational features.  On the left is a list 
of molecules including macromolecules and ligands. For 
single ligand docking click on the ‘AutoDockTools’ icon 
which brings up the docking menu. Work from left to right 
across the ADT toolbar.  After reading in your macromolecule 
and ligand, there are a number of preparative steps required to 
prepare both the macromolecule and ligand for a docking 
analysis.  A key step is the preparation of a new file format 
(*.pbdqt).  It is then optional to define any flexible residues in 
the macromolecule.  After this, the user needs to define a grid 
box to define an area of the macromolecule over which the 
docking analysis will take place.  If key binding residues are 
known, this is a relatively simple process and is performed 
with a three dimensional graphical aid.  Too large a grid box 
may result in a long processing time, and too small may 
prevent accurate results. For our analysis in both SwissDock 
and AutoDock we defined the Gridbox with centroid for x, 
27.00Å; y, 2.00Å and z, 2.75Å and dimensions x and y, 
15.00Å: z, 12.00Å (Figure 2).       
 
Figure 2: Grid box display in ADT. 
 
After the grid box has been defined the user can now save 
this (as a *.gpf file) and choose both the macromolecule and 
ligand file to be used for docking (these must be pre-prepared 
as described earlier).  Also the user must now define other 
docking parameters, these are also prefilled with default 
values for novice users.  After this, the docking parameter file 
must be generated as a *.dpf file which will be used for the 
docking run.         
 
At this stage the user is ready to firstly run AutoGrid and 
then AutoDock from within the GUI.  AutoDock relies on the 
results generated by AutoGrid and expects to find these in the 
working directory.  AutoDock can now be run.  After the 
process has competed, the docking results can be reviewed 
using the “analyze” features of ADT.    
 
Table 2: Practical Guide to MD using AD4. 
 
Step Task Comments/Recommendations 
1 Prepare 
directories for 
use 
Create new folders for .pdb and ligand files. (avoid 
spaces in the pathname). 
2 Prepare 
software for use 
Open ADT, set working directory to the folder 
created in step 1. 
File>Preferences>Set 
3 Prepare the 
macromolecule 
Delete water molecules. Add hydrogens. Use ‘grid’ 
menu to save the molecule as a .pbdqt file.   
Gasteiger charges are added automatically. 
Edit>Delete Water 
Edit>Hydrogens>Add 
Grid>Macromolecule>Choose 
4 Prepare the 
ligand 
Open ligand file from “ligand” menu. Gasteiger 
charges are automatically added. Ligands 
(in.mol2format) must have hydrogens already 
added. 
Ligand>Input>Open 
5 Prepare the 
ligand 
Use “torsion tree” to define a central atom (root) 
before “choose torsions” to choose rotatable 
(active) bonds. Save ligand as a .pdbqt file.   
Ligand>Torsion Tree>Detect Root 
Ligand>Torsion Tree>Choose torsions 
Ligand>Output>Save as PDBQT 
5 Define grid box Grid box represents search space for docking 
process.  Define area using GUI by dragging box 
over the molecule, or type in the parameters 
manually.  
Grid>Macromolecule>Choose 
Grid>Grid Box... 
6 Set map types By choosing a ligand, the map types used for the 
AutoGrid calculations can be automatically 
identified. A .gpf file can now be saved that will 
define the parameters for the AutoGrid process. 
Grid>Set Map Types>Choose Ligand 
Grid>Output>Save GPF 
7   Run AutoGrid AutoGrid will run using the .gpf file. Output files 
are found in  working directory. 
Run>Run AutoGrid 
8   Prepare target 
and ligand 
Choose the macromolecule and the ligand. Set the 
docking parameters, these are prefilled with default 
values.  Output a “Lamarckian GA” to produce the 
.dpf file that contains the parameters for AD4. 
 
Docking>Macromolecule>Set Rigid Filename 
Docking>Ligand>Choose 
Docking>Search Parameters>Genetic Algorithm 
Docking>Output 
9   Run AD4 Using the .dpf file AD4 will run and produce output 
files in the working directory. 
Run>Run AutoDock 
10 Visualize 
Results 
From the “Analyze” menu it is possible to show the 
conformations, ranked by energy, and visualize 
these with the ligand and macromolecule. 
 
After AD4 has been used in the manner described above to 
dock a single ligand, it is possible to then use PyRx for the 
automated screening of a ligand library.  PyRx can use the 
.pdbqt files produced by ADT, or can generate its own.  This 
case study will assume the prior tasks have already been 
completed, and files from the same working folder can be 
used. 
 
Table 3: Practical Guide to Virtual Screening with PyRx. 
 
Step Task Comments/Recommendations 
1 Open PyRx PyRx generates its own working folder each 
time.  To reset PyRx, delete this folder.  Copy 
this folder as a backup. 
2  Select AD4 
wizard 
AutoDock Wizard>Start Here 
3  Choose local 
installation 
Checkbox “local”. Click “start” button. 
4  Select Molecules Select the ligand files for the library search 
(these can be unprepared .mol2 files).   
Select the macromolecule file, it is convenient 
to use the pre-prepared .pbdqt file from the 
previous exercise.   
Click “Add Ligand” 
Click “Add Macromolecule” 
Click “Forward” 
6  Run AutoGrid Using the GUI, select the box size making sure 
to cover the target area. 
Click “Run AutoGrid” 
7  Run AutoDock Options exist to change the docking 
parameters. “Lamarckian (GA)” and 
“Maximum number of energy evaluations: 
short”.  A short setting for maximum number of 
energy evaluations hastens the docking process 
at the cost of accuracy.   
Click “Run AutoDock” 
8 Analyze Results Results are provided in the form of a table 
ranked by binding affinity.  Clicking on a table 
entry highlights the ligand in the three 
dimensional view.  
 
2.2.3 MD using SURFLEX-DOCK 
Since SYBYL users have access to a high level of 
supporting material, we have refrained from reproducing it 
here. Instead we have included that which is necessary to 
perform a basic docking run for comparative purposes with 
the other programs.  
 
Protomol Generation: 
The Surflex-Dock protomol is a computational 
representation of the intended binding site to which putative 
ligands are aligned. The protomol is not meant to be an 
absolute docking envelope (Figure 3). Its purpose is to direct 
the initial placement of the ligand during the docking process. 
Docked ligands are scored in the context of the receptor, not 
in the context of the protomol. Protomol generation in 
Surflex-Dock is described by Jain.[54] 
Figure 3: Surflex-Dock protomol: transparent surface coloured by lipophilic 
character (bloat 10, threshold 0.5). Wild type hAR (PDB ID: 2PNU). Key 
binding site residues blue; X-ray ligand, EM7544, atom types. 
 
Scoring Functions: 
Surflex-Dock incorporates a scoring function, Total Score, 
expressed as pKD. An advantage of the Surflex-Dock 
algorithm is that it includes consideration of hydrophobic, 
polar, repulsive, entropic and solvation terms. The results also 
provide a breakdown of the total score into polar and repulsive 
contributions in terms of ‘crash’ and ‘polar’ scores. The 
smaller the crash score, the better Surflex-Dock is at screening 
out false positives. However, this may discard true positives 
that fit tightly in the pocket.[55, 56] 
 
Protein flexibility can be incorporated at various levels of 
complexity from hydrogens to heavy atoms. Protein 
movement takes place in a second Surflex-Dock run, 
producing additional score set and accessible in the results 
browser. More consistent results can be produced by 
increasing the number of starting conformations. 
 
Table 4: Practical Guide to MD using Surflex-Dock. 
 
Step Task Commands Comments 
1 Prepare 
ligand 
database 
 
Create a ligand dataset. If 
using ChemDraw save in .sdf 
format to be read by SYBYLx-
2.1. Import into Sybylx-2.1.1 
and save in a new molecular 
database. Save as single .mol2 
files and translate to .sln 
format. 
*Ensure correct atom 
Types.  
Add hydrogens and 
charges. Minimize 
energy.  
(Our parameters:- 
Gasteiger-Hűckel 
charges, 
Amber7FF99 force 
field,[16] 
Conjugated. 
Termination 
conditions:  
E<0.050 kcal/mol) 
2 Prepare 
Target  
>Applications>docking 
suite>dock ligands 
>Select docking mode*. 
>Define protein 
1. Extract ligand from .pdb 
We recommend using 
GeomX for more 
exhaustive & 
accurate docking. 
Trade off with time. 
2. Add charges and hydrogens 
to target 
3 Define 
Protomol 
Select from three modes to 
define conformational search 
space. Ligand (if crystal ligand 
exists) Residues (if site is 
known) or Multichannel where 
potential binding sites are 
predicted.  
Determine optimal values for 
parameters threshold and 
bloat.  
Threshold 
(buriedness)  –
between 0.01-0.99. 
(Default 0.50).  
Tip: Increasing 
threshold decreases 
volume.  
Bloat (inflates 
protomol). Default 
0Å otherwise 
between (0-10Å.) 
4 Set up 
Docking 
parameters 
Options for flexible target 
docking mode, either 
‘hydrogens’ only or key 
‘heavy atoms’  
 
Select appropriate ligand. 
Flexible sidechains  
vastly increases run 
time. Test system 
firstly without 
flexibility.  
5 Select 
Reference 
Ligand   
 
.mol2 file or from a molecular 
area 
Automatically 
extracted in Ligand 
Mode. 
6 Select 
Number of 
Starting 
Conformatio
ns 
 
Select 4 if using flexible 
‘Hydrogens’ or 6 if selecting 
heavy atom flexibility. 
Produces more 
consistent results 
especially in 
flexibility mode.  
7 Run Choose a file name and run 
docking. 
Include total cores 
desired for run if 
applicable on your 
system. 
8 Analysis of 
results    
Select Results file and browse 
results. 
>Applications>Docking 
Suite>Analyze results 
Display and analyze within 
Sybylx2.1.1. Convert to 
spreadsheets to view and 
compare parameters, conduct 
bioinformatics, QSAR, 
correlations etc. 
Ligands can be 
displayed in/with the 
protein; site; 
reference ligand; or 
protomol. 
 
 
2.3 Homology Modelling using Swiss-Model 
For this section we chose the sequence of the human ATP-
gated, ion channel P2X1 receptor as no crystal structures 
currently exist and thus a relevant example.  A model was 
built using Swiss-Model, based on the closest sequence 
available, that of the zebrafish P2X4 (PDB ID: 4DW1) 
receptor with a sequence identity of 45.8%.  
 
Search results for the human P2X1 purinergic receptor 
sequence revealed 10 potential templates with the highest 
sequence identity with the P2X4 receptor with a sequence 
identity of 45.8 (Supplemental Figure S2). A clear picture of 
how close the sequences are to the query sequence can be 
displayed via the sequence similarity tab which depicts a 
cluster graph of the sequences. 
 
We selected the 4DW0 for a template based on the highest 
global model quality estimation (GMQE) score of 0.68. This is a 
quality estimation which combines properties from the target-
template alignment. The resulting 3D structure, shown in 
Figure 4 (and corresponding sequence alignment in 
Supplemental Figure S3) shows sections of secondary 
structure coloured blue for high quality areas and orange for 
low quality areas. Residues in the alignment can be selected 
interactively which automatically identifies their 3D position 
in the model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Template produced from query sequence of human P2X1 and target 
structure of 4DW0. 
 
In this case, all three gaps shown in the alignment 
correspond to surface loops of the extracellular domain of the 
receptor rather than amid core -sheets or helices. Thus the 
model could reasonably be considered for further molecular 
modelling projects.  
 
Table 5: A Practical Guide to Homology Modelling. 
 
Steps Task Comments 
1 >Retrieve query 
sequence (see notes on 
‘Obtaining Target 
(query) Sequences)’. 
Connect to NCBIa, enter protein name 
including species. Select ‘protein’ in the 
database window. Select appropriate 
sequence, save in FASTA format. (Tip: 
save as a .txt file). 
2 Conduct a multiple 
sequence alignment 
(MSA) (optional) 
(see notes on MSA). 
The following tools provide options for 
conducting MSAs: ClustalOmegab or T-
Coffeec. 
 
4 Select 
>Start Modelling 
Navigate to the SwissModeld site to start a 
new modelling project. 
5 Upload sequence 
(FASTA format) then 
select  
>Search for 
Templates 
Templates will provide a number of 
possible 3D structures and their sequence 
identities to the query sequence. 
6 View Output. 
Compare by selecting 
the top few matches.  
Select templates to compare 
superimpositions in the viewer. Note the 
%Coverage column. Many sequences and 
targets contain only fragments of the entire 
sequence. It is important to match relevant 
domains of your protein for your model 
such as that containing the binding site.  
7 Inspect the alignment 
and check for gaps.  
To analyse gaps more 
closely:- 
>View Project in 
DeepView. (see notes 
on Deepview) 
 
(See Notes – Dealing with Gaps in 
Sequences)  
Analyse superimposition for any 
unresolved residues in the template. 
Identify positions of any gaps in either 
template/query sequence that may impact 
on the overall reliability of the model. 
Tip: Comparing secondary structure 
alignment is useful. For example, gaps in 
loops are usually permissible. Gaps in -
sheets may be more hazardous to the 
overall 3D model structure. 
8 Select appropriate 
template and select  
>Build Model 
Comparing multiple models (via 
superimpositions) is useful to identify the 
most appropriate model. 
 Save model in .pdb file 
format. 
Additionally save the 
model file. 
A simple viewer is available in 
SwissModel but more powerful freeware 
programs are available to visualize, 
display and manipulate your models, 
including superimpositions. We 
recommend Chimera. [53] 
a[57], b[58], c[59], d[60] 
Obtaining Target (query) Sequences 
When searching the NCBI Protein database for amino acid 
sequences, retrieval of relevant information is fast and specific 
if using appropriate Boolean expressions. For example, to 
search for a sequence for the human P2X1, enter 
‘human+P2X1+receptor AND “Homo sapiens”’. Four entries 
were retrieved at the time of writing. Note that links are 
available for downloading the sequence in FASTA format 
which should be saved as a .txt file. (Edit in Notepad+ if 
required.)  
 
Multiple Sequence Alignments (MSAs) 
It may be the case that there are a number of sequences for 
relevant proteins with which to compare with your target 
protein or template. MSAs are common tools in many 
molecular biology projects for visualizing differences in 
amino acid sequences which translate to structural difference 
that may impact on function. 
 
DeepView 
In other cases where sequence alignment is not straight 
forward and insertions or deletions may be present, Swiss-
Model has a structure viewer called DeepView which can be 
useful for making alterations prior to building the final model. 
Users with a deeper understanding of protein structure will 
find this process easier.   
 
Dealing with Gaps in the Sequences 
Gaps in the template sequence are due to insertions (or 
deletions) during the sequence alignment process whereas 
gaps in the query sequence means the two residues flanking 
the gap, while peptide bonded in the 3D model, could be far 
apart in the sequence. 
 
When residues in the query sequence are untemplated, that 
is, there are no corresponding template residues, these are 
given a high temperature factor in the 3D model and can be 
easily selected for and visualized. Luckily long regions of 
untemplated residues can be visually easy to spot as they are 
often represented by hairpin loops extending out from the 
more compact protein structure.  
 
In some cases, highly mobile residues which result in 
unresolved electron density and thus residues without 
coordinates in the template are not included in the sequence 
alignment nor indicated by a gap. This causes a splice in the 
template sequence effectively shifting the query-template 
alignment. The resulting homology model then will not reflect 
the presence of these residues. One way to avoid this is by first 
analyzing the structural alignment in DeepView. After visual 
inspection, the sequence of target/template may be carefully 
altered if needed or utilized in an MD protocol.  
 
3. Results & Discussion 
The MD case study aimed to compare the docked poses of 
a series of selective androgen receptor modulators (SARMs) 
into the hAR followed by a brief analysis of the results. 
Antiandrogens antagonize the actions of testosterone or 5α-
DHT by competing for AR binding sites and may be steroidal 
or non-steroidal in structure. A small subset of what is 
otherwise a vast array of known SARMs was selected for this 
comparative demonstration. These include the natural 
substrate, testosterone and its active form, 
dihydroxytestosterone (DHT), steroidal androgen with high 
affinity, R1881, cyproterone acetate, a weak antiandrogen 
with high binding affinity, a number of non-steroidal 
antiandrogens including the clinically relevant, flutamide and 
bicalutamide and a number of other potential hAR 
modulators. A non-steroidal decoy of similar structure to the 
non-steroidal hAR modulators was obtained from the ZINC 
database [61] which reportedly does not bind the hAR.  
 
The biological, physical and chemical properties of the 
ligands set out in Supplementary Table S1 are helpful in the 
interpretation of docking results to assess potential 
correlations relating to size, shape, polarity etc. These will be 
discussed in the next section. 
3.1 Comparison of Docking Results 
Analysis of docking results is often a complex task and is 
usually conducted by visual screening of the docked poses in 
their respective binding sites.  Some programs can display the 
results including intermolecular hydrogen bonding which aids 
in lead identification. For example, Figure 5 shows the docked 
pose of EM7544 from wild type hAR with three hydrogen 
bonds to key binding site residues. Importantly, one key 
residue, T877, is the mutated residue displayed in the mutant 
T877A hAR. The replacement of threonine’s hydroxyl group 
with the small side chain of alanine creates a larger binding 
site in the mutant enabling a larger array of compounds to 
enter leading to receptor promiscuity. 
 
Figure 5: Docked pose of EM7544 (atom colours) from 2PNU (wild type 
hAR) depicting three intermolecular hydrogen bonds (yellow). Key binding 
site residues are shown in blue. 
 
A comparison of each docking program was conducted to 
assess how well each was able to reproduce the orientation of 
the crystal ligand in the native and mutant receptor. A root 
mean square deviation (rmsd) of less than 2Å is generally 
acknowledged as acceptable performance. Note that this 
guideline assumes that the crystallized orientation is the active 
orientation, however; it is arguable that this may rarely be the 
case.  
 
Figure 6 shows the orientations of the extracted ligand, 
EM5744, from 2PNU and respective superimposed docked 
ligands. It is clear that SwissDock performed least well on the 
basis of the above criteria. Both AD4 and Surflex-dock 
reproduced the orientation of the crystal ligand more closely 
although superimposition shows the Surflex-dock result to be 
an order of magnitude closer. 
 
 
 
 
 
 
 
 
Figure 6: Conformation superimposition of docked EM5744 using: 
SwissDock (magenta, RMSD 4.15Å), AD4 (orange, RMSD 2.69Å) and 
Surflex-Dock (cyan, RMSD 0.39Å) with the conformation of EM5744 
extracted from PDB ID: 2PNU (atom colours).  
 
For the mutant hAR (PDB ID: 20Z7), however, SwissDock 
outperformed AutoDock in terms of comparison of rmsd of 
docked versus X-ray ligand conformations. Figure 7 shows 
the orientation of the extracted X-ray ligand, cyproterone 
acetate, from 2OZ7 superimposed with respective docked 
ligands using the 3 programs. Surflex-dock’s showed a 
consistently high level of performance. 
  
 
 
 
 
 
 
 
Figure 7: Conformation superimposition of docked cyproterone acetate 
using: SwissDock (magenta, RMSD 0.83Å), AD4 (orange, RMSD 8.80Å), 
Surflex-Dock (cyan, RMSD 0.71Å) and 2OZ7 X-ray ligand (atom colours).  
 
Inter-program variations between algorithms are 
highlighted in Table 6 and 7 where we compared ligand 
ranking within the steroid binding sites of wild type hAR 
(2PNU) and mutant hAR (2OZ7) with both flexible and rigid 
target atoms. By comparing ligand ranking we avoid the 
complexity of non-uniformity in units of scoring between the 
various programs. Overall, incorporating flexible target atoms 
5Å or less from any atom of the ligand made little difference 
in the SwissDock analysis although introducing flexibility 
boosted both wild type and mutant X-ray ligands top ranking 
positions from midfield. A similar trend was observed for the 
AutoDock analysis with little change in ranking by 
introducing flexibility. Interestingly Surflex-Dock produced 
more significant changes to ranking on the introduction of 
flexibility with the triazole compounds and flutamide showing 
a much higher ranking.  
 
The grid box dimensions were kept consistent for 
AutoDock and SwissDock. Since Surflex-Dock utilizes a 
protomol instead to define ligand conformational search 
space, every effort was made to keep the overall area 
consistent. Note the volume of the wild type hAR binding site 
is somewhat smaller than the T877A mutant due to the 
reduction in side chain size as well as removal of a hydrogen 
bonding group. This mutation contributes to the development 
of treatment resistance in prostate cancer by driving receptor 
activation by the same compounds that initially acted as 
antagonists to the hAR.[62] 
 
The flexibility of target atoms appeared to make minimal 
difference to ranking by AD4 in wild type hAR though more 
noticeable changes in the mutant site was observed. The 
largest change in ranking going from rigid to flexible target 
was with cyproterone acetate and R1881 where their positions 
were reversed from first to fourth respectively.  
 
Analyzing the data from a biological interest viewpoint, 
that is, comparing the ranking of each ligand from wild type 
to mutant, revealed no change for the majority of ligands in 
the SwissDock analysis with a preference for the steroidal 
ligands. A similar trend was observed for AutoDock while 
Surflex-Dock showed a high degree of rank change going 
from wild type to mutant sites. Here no clear preference for 
steroidal was observed with triazole compound 39S ranking 
third. The X-ray ligand, EM7544 (from wild type target) was 
ranked 10th in the wild type to first in the mutant site. Similar 
results were observed for the X-ray ligand, cyproterone 
acetate (from the mutant target). Whether this is simply an 
artefact of the Surflex-Dock protocol of ligand-based 
protomol generation or may have any biological significance, 
is not known.  
 
Table 6: Comparison of Ligand Ranking in wild type hAR. 
Liganda Type Rigid Flexible 
  SWD A
D4 
SF
D 
SW
D 
AD
4 
SF
D 
testosterone Native  1 2 4 3 2 6 
DHT Native  2 3 6 1 3 7 
EM7544 
(2PNU) 
Steroidal 
high 
affinity  
6 8 1 4 6 2 
Cyproterone 
acetate 
(2OZ7) 
Steroidal 
inhibitor  
9 1 10 2 4 8 
R1881 Strongly 
binding 
androgen 
4 4 5 6 1 9 
Bicalutamide Non-
steroidal 
inhibitor  
5 6 8 7 5 10 
Flutamide Non-
steroidal 
inhibitor  
3 7 7 5 8 11 
CHEM 
366105 
(active) 
Non-
steroidal 
inhibitor  
8 9 2 9 10 1 
Triazole cpd 
39S 
Non-
steroidal 
inhibitor  
11 11 11 11 9 3 
Triazole cpd 
39R 
Non-
steroidal 
inhibitor  
10 10 9 10 7 5 
Zinc1284867
8 (decoy) 
Non-
steroidal 
Decoy 
7 5 3 8 3 4 
 
Analysis of the SwissDock results showed the smaller 
ligands obtaining a higher ranking in the both sites whether in 
a rigid or flexible target. The only anomaly in this trend was 
cyproterone acetate whose ranking increased in a flexible site. 
The flexible alkyl tail of this ligand may partly account for 
this observation. The larger compounds tended to rank lower.  
  
In the wild type site only Surflex-Dock ranked the X-ray 
ligand first or second top scoring pose for both flexible and 
rigid docking. It is worth noting that these ligands are used as 
reference ligands in the docking protocol and may, as a result, 
bias this ligand towards the top. For the larger mutant site 
however all three programs ranked the X-ray ligand top score 
when run in flexible mode but only Surflex-Dock did so in 
rigid mode.  
 
The triazole compounds were ranked low by all programs 
in flexible and rigid modes for the larger mutant site. The 
same results was found for the rigid mode docking within the 
wild type site however Surflex-Dock ranked them much 
higher in flexible mode compared to the other programs.  
Table 7: Comparison of Ligand Ranking in mutant hAR. 
 
Liganda Type Rigid Flexible 
  SW
D 
A
D4 
SF
D 
SW
D 
AD
4 
SF
D 
testosterone Native 
ligand 
2 1 5 5 4 9 
DHT Native 
ligand 
3 2 3 3 3 7 
EM7544 
(2PNU) 
Steroidal 
high 
affinity 
ligand 
faile
d 
8 11 2 5 2 
Cyproterone 
acetate 
(2OZ7) 
Steroidal 
inhibitor  
6 4 1 1 1 1 
R1881 Strongly 
binding 
androgen 
7 3 6 6 2 10 
Bicalutamid
e 
Non-
steroidal 
inhibitor  
4 7 7 7 6 5 
Flutamide Non-
steroidal 
inhibitor  
1 6 4 4 8 11 
CHEM 
366105 
(active) 
Non-
steroidal 
inhibitor  
8 11 9 9 10 8 
Triazole 
cpd 39S 
Non-
steroidal 
inhibitor  
9 10 8 11 11 3 
Triazole 
cpd 39R 
Non-
steroidal 
inhibitor  
10 9 10 10 9 6 
Zinc128486
78 (decoy) 
Non-
steroidal 
Decoy 
5 5 2 8 7 4 
 
Post MD processing capabilities within Surflex-Dock 
include the ability to convert MD data into a molecular 
spreadsheet in which other physical or chemical properties 
can be added for each ligand to find potential correlations. 
Figure 8 and 9 compared the results for ligands docked into 
the wild type hAR and mutant sites respectively in flexible 
mode. The highest degree of correlation was found between 
molecular weight and total score (Figure 8) and number of 
rotatable bonds with total score (Figure 9). In both bases we 
also have coloured by clogP. A trend in both sites was 
observed whereby higher scores were given for larger and 
more flexible compounds with a higher degree of 
lipophilicity.  
 
The consensus between six algorithms of Surflex-Dock 
provides an additional layer of interpretation of the results. 
Total scores and ranking should only be assessed alongside a 
visual inspection of the docked poses where predicted binding 
interactions can be checked for validity, comparison to those 
that may be important for native ligands or existing inhibitors 
and also if the volume of the grid is sufficient to encapsulate 
the binding pocket. The Cscores are set out in Supplemental 
Table S2 where ligands can be assessed on the basis of 
consensus and compared to their ranking. Interestingly few of 
the ligand total scores showed a high level of consensus. 
Interestingly the triazole S enantiomer produced a Cscore of 
6 (highest). This compound was shown to score highly in the 
mutant site. Note that for the Surflex-Dock analysis only the 
top scoring poses within each cluster was selected. 
 
Further quantitative structure-activity relationship (QSAR) 
and CoMFA analyzes can be performed within the Surflex-
Dock GUI if biological data is available.  
Figure 8: MD results from Surflex-Dock for wild type hAR site (PDB ID: 
2PNU) in flexible mode. Partial least squares correlation of molecular weight 
(r2=0.383) and rotatable bonds (r2=0.412) with total score and coloured by 
clogP. 
Figure 9: MD results from Surflex-Dock for mutant hAR site (PDB ID: 
2OZ7) in flexible mode. Partial least squares correlation of molecular weight 
(r2=0.307) and rotatable bonds (r2=0.214) with total score and coloured by 
clogP. 
Interestingly, the decoy ligand, ZINC12848678, scored 
second position after the X-ray ligand in the mutant hAR site. 
This relatively small, charged ligand appears to prefer the 
larger site created by the mutation and can take advantage of 
hydrogen bonding groups around the site providing plenty of 
possible polar interactions for ligand stabilization.  
 
Figure 10 shows the orientation of testosterone in the wild 
type hAR site overlaid with the docked position of 
antiandrogen, bicalutamide, and also a triazole non-steroidal 
hAR inhibitor, compound 39. The lipophilic moieties are 
closely aligned in the steroid binding site. The more polar ends 
of the non-steroidal inhibitors orient towards a narrow 
channel, the end of which is capped by a key  helix with a 
role in receptor activation.   
Figure 10: Superimposition of testosterone (magenta), bicalutamide (atom 
types) and triazole compound 39 (atom types with FMoc group) 
Where available, biological activity data for relevant 
ligands was collected and set out in supplementary Table S1. 
This data, along with physical and chemical properties of the 
ligands, can be further used in a quantitative structure-activity 
relationship (QSAR) analysis – a useful technique in design 
optimization. It must be noted that a robust docking analysis 
would often incorporate the use of a large training dataset of 
actives and decoys which would then be further optimized 
through ligand enrichment and visualization of cluster 
orientations and ranking prior to use with a test dataset.  
 
A limitation of this study was the small ligand database. 
This was specifically made small for illustrative purposes. 
Furthermore a thorough docking analysis of the hAR would 
take advantage of the entire available dataset of active and 
decoys for the hAR from which incorporating a ligand 
enrichment protocol would facilitate a higher likelihood of the 
algorithm’s capacity to select high affinity ligands. 
 
 
 
 
 
3.2 MD program comparison 
The docking case study presented here provided a means 
upon which to compare the usefulness of the three selected 
programs. To further facilitate choice of MD program we have 
summarized from key features which may be of assistance in 
the selection of a suitable MD program (Table 8). While the 
results from our MD case study showed variability in the 
metrics used to compare the various programs, produce a clear 
winner in terms of reliability of results. Benchmarking 
between the most commonly used algorithms, such as that 
used by AD4 and Surflex-Dock, has shown a good level of 
performance. From our results we found both AutoDock and 
Surflex-Dock produce high quality results. Our results 
showed AutoDock to be superior for active pose prediction 
while Surflex-Dock was more consistently able to predict X-
ray ligand orientation. In overall usability however, especially 
for multiple ligand docking, we found Surflex-Dock to be 
most useful.  
 
Table 8: Summary of selected MD programs. 
 
Feature SwissDock AD4 Surflex-Dock 
Availability Freeware Freeware Commercially 
available as a module 
of SYBYLx2.1 suite  
Beginner-
freindly 
Easy to 
Moderate 
Moderate Moderate 
Min. 
Hardware 
Requirement 
desktop 
PC.  
Intel i86 (32-
bit), x86_64 
(64-bit) 
processor. 
Intel i86 (32-bit), 
x86_64 (64-bit)/ 
PowerPC processor. 
Operating 
System 
Server/cros
s platform. 
Cross platform Cross platform. 
Applicability Single or 
multi 
target  
Robust and 
accurate single 
target/single 
ligand (option 
for multiple 
ligand)  
Robust and accurate 
single target– multiple 
ligand modelling. 
ForceField CHARMM CHARMM AMBER 
(a range of options are 
provided). 
Advantages Intuitive 
online 
server, 
widely 
utilised in 
literature. 
Freeware, 
robust, gold 
standard. 
Benchmarking 
shows a good 
level of docking 
accuracy. 
Good level of docking 
accuracy, short run 
times, handles  large 
ligand libraries, GUI, 
high level of 
parameter control and 
support.  
Limitations Server-
based. 
Min. 
parameter 
control, 
support via 
help 
forum. 
Long run times, 
max. 32 torsion 
angles, limited 
support via 
forum. Separate 
GUI for virtual 
screening. 
Commercially 
available. Less 
commonly used in 
Industry for 
comparative purposes. 
3.3 Homology Model Results 
 
Residues in the alignment can be selected interactively 
which automatically identifies the 3D position in the model. 
In this case, all three gaps were found to correspond to loops 
on the surface of the extracellular domain of the receptor 
rather than core -sheets or -helices regions thus the model 
could reasonably be considered for further molecular 
modelling projects.  
 
A superimposition depicting ribbons through the backbone 
atoms of template and target is shown in Figure 11. Despite 
the relatively low sequence identity between the template and 
target, the rmsd between the backbone of the proteins was 
remarkably good. The process can be repeated with a number 
of the high scoring matches. These may be compared to 
determine the degree of general agreement in 3D structure. 
Once satisfied, the best homology model could be utilized for 
subsequent MD, molecular dynamics or other receptor-based 
analyzes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Superimposition of the template crystal structure of human P2X4 
receptor (PDB ID:  4DW1) with the final homology model using the sequence 
of human P2X1. 
 
 
 
 
 
4. Conclusion 
This review aimed to serve as a practical guide to 
contemporary molecular docking by providing a detailed, 
step-by-step workflow for docking a set of ligands into a 
target. By selecting three MD programs covering a range of 
user preferences, we were also able to illustrate the necessity 
for validation and benchmarking in MD.  Additionally, where 
the specific 3D target structure is unavailable, we guide the 
reader through a homology modelling case study to facilitate 
generation of a model structure upon which subsequent MD 
may be applied. We hope this tutorial review may be of 
assistance to those interested in incorporating these in silico 
techniques into lead identification strategies.  
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